Skip to content
★ Sign in to follow
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. Stock: price and insider trades · China

华大基因

CN·Mcap CN¥16.2BHealth Care

No insider purchase over the last 90 days. The latest, by 王玉珏, was filed 29 Aug 2024.

BGI Genomics Co., Ltd.: what insiders have been doing

Headquartered in Shenzhen, People's Republic of China, BGI Genomics Co., Ltd. belongs to the Health Care sector and traces its origins to 1999. Filings by its managers are published through SSE / SZSE (CSRC). Nothing new has been filed by managers of BGI Genomics Co., Ltd. in twelve months, the latest record being from 22 September 2025.

Looking back to 2021, when coverage begins, insiders filed 3 purchases and 1 sale.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Key facts

Headquarters: Shenzhen, People's Republic of China · Founded: 1999

Source: Wikidata (CC0).

Insider Decl.
4
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€88M
1 ops. · all time

Who traded when

BuySale
深圳华大基因科技有限公司1 sale

Since the insiders bought

  • Filed 29 Aug 2024 · 801 days ago · €88k
    +49.1%
    Entry CN¥36.16 · Close at T+365 CN¥53.92
  • Filed 28 Jan 2022 · 1745 days ago · €875k
    -36.4%
    Entry CN¥86.29 · Close at T+365 CN¥54.85

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 22,709 of 26,897 companies
27.0
score / 100
Value
25
Quality
29
FCF yld-3.5%
Earn yld-3.8%
EV/EBITDA·
ROE-6.6%
Gross mgn38%
Net mgn-17%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥38.77
Analyst consensus
1 analysts
·
CN¥51.14Target CN¥51.14(+32%)CN¥51.14
Income statement
RevenueCN¥3.7B
Gross profitCN¥1.4B38% margin
EBITDA-CN¥48.3M-1% margin
Net income-CN¥616.7M-14.9% margin
Valuation
PER (forward)228.1x
P/Book1.9x
Beta0.66
Balance sheet & cash
Market capCN¥16.2B
Total debtCN¥640.4M
Free Cash Flow-CN¥569.1M
Debt / Equity6%
Profitability & ownership
ROE-6.6%
ROA-2.5%
% insiders39.2%
% institutions5.9%
Last declaration on 22 September 2025
Declarations4 total
  • ▼
    Related company / holdingExecutives
    738M CNY30SZSE
    16,732,683 shares100.0% of flowA股XSHESZSE:173000009569624260
  • ▲
    董事,高管Executives
    688,817 CNY15SZSE
    19,300 shares100.0% of flowA股XSHESZSE:173000008052297100
    Canonical exit: 27 Nov 2024 (T+90)
  • ▲
    董事Executives
    6M CNY11SZSE
    74,000 shares42.2% of flowA股XSHESZSE:173000005350203740
    Canonical exit: 28 Apr 2022 (T+90)
  • ▲
    董事Executives
    9M CNY13SZSE
    105,500 shares57.8% of flowA股XSHESZSE:173000005186031170
    Canonical exit: 21 Mar 2022 (T+90)

4 of 4 declarations

About BGI Genomics Co., Ltd.

华大基因 is a genomics company that provides sequencing and genetic analysis services. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations